Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate.
Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate.
复制标题
DOI:
10.3389/fphar.2020.594574
复制
发表时间:
2020
影响因子:
5.6
通讯作者:
Stec DE
中科院分区:
文献类型:
--
作者:
Hinds TD Jr;Creeden JF;Gordon DM;Stec DF;Donald MC;Stec DE
The inverse relationship of plasma bilirubin levels with liver fat accumulation has prompted the possibility of bilirubin as a therapeutic for non-alcoholic fatty liver disease. Here, we used diet-induced obese mice with non-alcoholic fatty liver disease treated with pegylated bilirubin (bilirubin nanoparticles) or vehicle control to determine the impact on hepatic lipid accumulation. The bilirubin nanoparticles significantly reduced hepatic fat, triglyceride accumulation, de novo lipogenesis, and serum levels of liver dysfunction marker aspartate transaminase and ApoB100 containing very-low-density lipoprotein. The bilirubin nanoparticles improved liver function and activated the hepatic β-oxidation pathway by increasing PPARα and acyl-coenzyme A oxidase 1. The bilirubin nanoparticles also significantly elevated plasma levels of the ketone β-hydroxybutyrate and lowered liver fat accumulation. This study demonstrates that bilirubin nanoparticles induce hepatic fat utilization, raise plasma ketones, and reduce hepatic steatosis, opening new therapeutic avenues for NAFLD.
登录
查看更多内容
影响因子:
5.6
作者:
Grabacka M;Pierzchalska M;Dean M;Reiss K
通讯作者:
Reiss K
影响因子:
2.9
作者:
Bawahab, Mohammed A.;Assiri, Abdullah S.;Haider, Syed Saleem
通讯作者:
Haider, Syed Saleem
影响因子:
4.8
作者:
Hinds, Terry D., Jr.;Stechschulte, Lance A.;Sanchez, Edwin R.
通讯作者:
Sanchez, Edwin R.
影响因子:
14
作者:
Kim, Jin Yong;Lee, Dong Yun;Jon, Sangyong
通讯作者:
Jon, Sangyong
影响因子:
4.8
作者:
Dong, Huansheng;Huang, Hu;Wang, Hongjun
通讯作者:
Wang, Hongjun